CarlieKennedyThompsonMD

PubMed

• 149 citations
  Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial
  Yiwey Shieh, Martin Eklund, Lisa Madlensky, S Sawyer, Carlie K Thompson
  Journal of the National Cancer Institute. 2017-01-27
• 55 citations
  Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
  Linda S. Lindström, Christina Yau, Kamila Czene, Carlie K Thompson, Katherine A. Hoadley
  Journal of the National Cancer Institute. 2018-07-01
• 42 citations
  How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support.
  Maurice J. Berkowitz, Carlie K Thompson, Laura Zibecchi, Minna K Lee, Elani Streja
  Journal of Cancer Survivorship. 2021-02-01

Journal Articles

• The WISDOM Study: breaking the deadlock in the breast cancer screening debate.  
  Esserman LJ, Anton-Culver H, Borowsky A, Brain S, Cink T, Crawford B, Eklund M, Esserman L, Fenton J, Heditsian D, Hiatt RA, Hogarth M, Kaplan C, Koenig B, LaCroix A, ..., NPJ Breast Cancer, 9/13/2017
• Putting the Great Mammography Debate to rest  
  Thompson CK, Eklund M, Esserman LJ, Am J Hematol Oncol, 1/1/2015

Abstracts/Posters

• Axillary staging is associated with better outcomes in women with small, estrogen-receptor positive breast cancers
  Thompson CK, Hunter-Squires J, Carlson KA, Kim S, Amersi F, Giuliano AE, Chung A, American Society of Breast Surgeons Annual Meeting, Orlando, FL, 1/1/2018
• Accuracy of pre-surgical imaging to guide surgical resection in patients with invasive breast cancer treated with neoadjuvant chemotherapy
  Carlson KA, Siegel E, Thompson CK, Kim S, Amersi F, Giuliano A, Chung A, American Society of Breast Surgeons Annual Meeting, Orlando, FL, 1/1/2018
• Comparison of survival outcomes in node-negative T1a and T1b high-risk breast cancer treated with and without adjuvant chemotherapy
  Carlson KA, Thompson CK, Kim S, Bao J, Amersi F, Giuliano A, Chung A, Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, 1/1/2018
• Are we overtreating DCIS?
  Thompson CK, Southern California Chapter of the American College of Surgeons Annual Scientific Meeting, Santa Barbara, CA, 1/1/2018
• The past, present and future of the neoadjuvant treatment of breast cancer
  Thompson CK, Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA, 1/1/2018
• The history of women in medicine
  Thompson CK, Grand Rounds, UCSF, San Francisco, CA, 1/1/2016
• Phenotype and immunophenotype analysis of gene expression defined �indolent risk� breast cancers
  Borowsky A, Thompson CK, Balassanian R, Yau C, Chen Y, Krings G, Nordenskjold B, Stal O, Fornander T, Esserman LJ, van�t Veer LJ, Lindstrom LS, United States and Canada Academy of Pathologists Annual Meeting, Seattle, WA, 1/1/2016
• Interobserver agreement of breast cancer IHC4 after �Score the Core� training
  Borowsky A, Balassanian R, Yau C, Engelberg JA, Thompson CK, Bishop JW, Cardiff R, Carpenter PM, Chen Y, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Lindstrom L, United States and Canada Academy of Pathologists Annual Meeting, Seattle, WA, 1/1/2016
• A pilot feasibility study of the WISDOM study, a preference-tolerant randomized controlled trial evaluating a risk-based breast cancer screening strategy
  Narasimmaraj PR, Stover Fiscalini A, Kaplan CP, van't Veer LJ, Hallada AM, Thompson CK, Theiner S, Borowsky A, Naeim A, Anton-Culver H, LaCroix A, Athena Breast Health..., San Antonio Breast Cancer Symposium, San Antonio, TX, 1/1/2015
• The feasibility of performing a preference-tolerant randomized controlled trial of personalized versus annual breast cancer screening
  Thompson CK, Kaplan CP, Wattles AG, Fiscalini AS, Tice, JA, Eklund M, Esserman LJ, Society of Surgical Oncology Annual Cancer Symposium, Houston, TX, 1/1/2015
• The rise in the rates of contralateral prophylactic mastectomy: can we personalize this decision?
  Thompson CK, UCSF Postgraduate Course, 1/1/2015
• Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival � retrospective analy...
  Lindstrom LS, Yau C, Czene K, Thompson CK, van�t Veer LJ, Nordenskjold B, Stal O, Fornander T, Benz CC, Borowsky A, Esserman LJ, European Cancer Congress, Vienna, Austria, 1/1/2015
• Identification of tumors with an indolent disease course: MammaPrint Ultralow signature validation in a retrospective analysis of Swedish randomized tamoxifen trial (STO)
  Esserman LJ, Thompson CK, Yau C, van�t Veer LJ, Borowsky AD, Tobin NP, Nordenskjold B, Fornander T, Stal O, Benz CC, Lindstrom LS, San Antonio Breast Cancer Symposium, San Antonio, TX, 1/1/2015
• Breast cancer screening in the precision medicine era
  Thompson CK, Fiscalini AS, Donnellan P, Kaplan CP, Madlensky L, Eklund M, Ziv E, van't Veer LJ, Tice JA, Esserman LJ, SABCS, San Antonio, TX, 1/1/2015
• The aggregate number of false-positive recalls and biopsies performed under different screening strategies in the US
  Thompson CK, O�Donoghue C, Ozanne E, Eklund M, Esserman L, SABCS, San Antonio, TX, 1/1/2014
• MammaPrint accurately predicts long-term survival (25 years) and adjuvant tamoxifen therapy benefit lymph node negative patients
  Lindstrom L, Benz C, Yau C, van�t Veer L, Thompson CK, Esserman L, San Antonio Breast Cancer Symposium, San Antonio, TX, 1/1/2014
• Improving the Care of Septic Patients: A Baseline Analysis and Quality Improvement Initiative
  Rajaram R, Kennedy C, Schwulst S, Bilimoria KY, NRSA Trainee�s Research Conference, San Diego, CA, 1/1/2014
• Striatal ascorbate-release dysfunction in murine models of Huntington's
  Dorner J, Barton S, Kennedy C, Murphy-Nakhnikian A, Rebec G, Society for Neuroscience, San Diego, CA, 1/1/2004
• Join now to see all

Other

• The effects of ceftriaxone on striatal ascorbate in Huntington's disease transgenic mice 
  Kennedy C, Thesis
  Indiana University